AIGISRx Envelope for Prevention of Infection Following Replacement With an Implantable Cardioverter-Defibrillator (ICD) (CITADEL)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
TYRX, Inc.
ClinicalTrials.gov Identifier:
NCT01043861
First received: January 5, 2010
Last updated: April 17, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to compare the incidence of cardiac rhythm management device (CRMD) infection and CRMD mechanical complication after CRMD replacement with an Implantable Cardioverter-Defibrillator (ICD) and AIGISRx Anti-Bacterial Envelope, to the incidence after replacement with an ICD and no AIGISRx.


Condition
Implantable Cardioverter Defibrillator Infection

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: AIGISRx Anti-Bacterial Envelope and Custom Mesh for Prevention of Infection Following Cardiac Rhythm Management Device Replacement With an Implantable Cardioverter-Defibrillator (ICD)

Resource links provided by NLM:


Further study details as provided by TYRX, Inc.:

Primary Outcome Measures:
  • Major CRMD Infection [ Time Frame: 3, 6, and 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • CRMD Mechanical Complication [ Time Frame: 3, 6, and 12 months ] [ Designated as safety issue: No ]

Enrollment: 465
Study Start Date: January 2010
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
CRMD replacement with ICD and AIGISRx
Patients who have undergone CRMD replacement with an ICD and the AIGISRx Anti-bacterial envelope, with or without lead revision (Prospective Arm)

Detailed Description:

Cardiac rhythm management device (CRMD) infection is associated with significant morbidity and expense. The frequency of CRMD infection is increasing faster than the frequency of CRMD implants, suggesting more effective prophylactic strategies are needed.

The AIGISRx Anti-Bacterial Envelope is an FDA-cleared polypropylene mesh that is intended to securely hold a pacemaker pulse generator or defibrillator (ICD) in order to create a stable environment when implanted in the body. It contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection in an in vivo model of bacterial contamination following surgical implant of the generator or defibrillator.

This is a prospective, observational, multicenter registry of subjects undergoing CRMD replacement with an ICD and AIGISRx, with or without lead revision/addition. The registry subjects will be compared to a published historical control group undergoing CRMD replacement with an ICD and no AIGISRx, with or without lead revision/addition. The primary study endpoints are major CRMD infection and CRMD mechanical complication during the 12 months following CRMD replacement with a ICD.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who have undergone CRMD replacement with an ICD, with or without an AIGISRx Anti-bacterial Envelope, at US medical centers.

Criteria

Inclusion Criteria:

  • Qualifying CRMD Implant procedure was replacement with a ICD and AIGISRx, with or without lead revision/addition
  • Received a complete AIGISRx Anti-Bacterial Envelope Model# 3122 or #3133 according to the Instructions for Use (IFU)
  • Clinically stable to tolerate procedure
  • 18 years or older
  • Able to return for follow-up care through the 12-month visit, or able to have referring physician provide follow-up data to study site by telephone

Exclusion Criteria:

  • Unable/unwilling to provide informed consent
  • Contraindication to receiving the AIGISRx device, in accordance with the package labeling
  • Pregnant or was at risk for becoming pregnant in the 30 day period following the Qualifying CRMD Implant
  • Current CRMD infection, or the indication for Qualifying CRMD Implant was replacement of CRMD that was explanted for infection
  • Clinical diagnosis of an active infection at the time of CRMD implant, including pneumonia, urinary tract infection, endovascular, cellulitis, bacteremia, or other major systemic infection. (Note: asymptomatic bacteriuria without UTI is not an exclusion criterion)
  • Generator replacement required planned lead extraction
  • Participating in another clinical study evaluating a drug or device designed to reduce cardiovascular rhythm management device infections
  • Life expectancy of less than 6 months
  • Expected to receive a heart transplant within 6 months
  • With the exception of the elderly in good mental health, all vulnerable subjects as defined by the FDA Office of Human Research Protection or local IRB will be excluded
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01043861

  Show 54 Study Locations
Sponsors and Collaborators
TYRX, Inc.
Investigators
Study Director: Steve A Sisk, MSc Pharmacy Medtronic/Tyrx, Inc.
  More Information

No publications provided by TYRX, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: TYRX, Inc.
ClinicalTrials.gov Identifier: NCT01043861     History of Changes
Other Study ID Numbers: CP-2009-1
Study First Received: January 5, 2010
Last Updated: April 17, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by TYRX, Inc.:
Defibrillator infection
ICD infection
Cardiovascular implantable electronic device infection
Infection
Defibrillators

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 26, 2014